New Delhi, Nov 5 (PTI) The government on Wednesday said it has extended funding to gene therapy pioneer ImmunoAct to scale up gene delivery systems to make the cancer treatment more accessible and affordable for patients.

The Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a breakthrough in cancer treatment that uses a patient's own immune system to fight certain types of cancer.

Clinical trials conducted globally have shown promising results in end stage patients, especially in patients suffering from Acute Lymphocytic Leukemia.

ImmunoACT, a spin-off company of IIT Bombay, has brought NexCAR19, the world's first humanised CAR-T therapy, to the market.

"The Department of Biotechnology via the Biomanufacturing initiative under the BioE3 Policy gave funding to ImmunoAct f

See Full Page